Step Away from the Money | GenomeWeb

Step Away from the Money

Premium

Tom Willis, who co-founded ParAllele BioScience and eventually sold it to Affymetrix, says that scientists who are pursuing their own dreams of starting a company should heed a simple rule: keep the fundraising to a minimum.

Most importantly, avoid venture capital for as long as you possibly can. "In general, I think a lot of companies can fail by trying to be companies too early," Willis says. "From the second that you take … cash from venture capitalists to the moment that you have to have some productive exit for investors … is a fairly narrow window."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.